Wednesday, May 31, 2023
  • Login
  • Register
No Result
View All Result
NEWSLETTER
Novichok (Moscow) Times
  • Home
  • CARTOONS
  • RUSSIA
  • COMING SOON
    • CZECHIA
    • RUSSIA
    • SWITZERLAND
    • USA
  • BELLINGCAT
  • THE INSIDER
  • NAVALNY
  • Home
  • CARTOONS
  • RUSSIA
  • COMING SOON
    • CZECHIA
    • RUSSIA
    • SWITZERLAND
    • USA
  • BELLINGCAT
  • THE INSIDER
  • NAVALNY
No Result
View All Result
Novichok (Moscow) Times
Home THE INSIDER

US Regulator Finalizes Pfizer Coronavirus Vaccine

by novichoktimes
August 23, 2021
in THE INSIDER
0
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter



The US Food and Drug Administration (FDA) on Monday finally approved the coronavirus vaccine developed by the US company Pfizer and its German partner BioNTech. About it reported in the press release of the regulator.

Pfizer is the first COVID-19 vaccine to receive final FDA approval. Prior to that – in December 2020 – Pfizer’s vaccine was fast tracked for emergency use by the FDA. Vaccines from Moderna and Johnson & Johnson later received similar approval.

“Today the FDA approved the first COVID-19 vaccine. The drug was known as [вакцина от] COVID-19 Pfizer / BioNTech, will now be marketed as Comirnaty [в качестве препарата] for the prevention of COVID-19 for persons aged 16 and over, ”it was reported.

As noted in the press release, as part of the previously issued authorization for the use of this vaccine in emergency situations, it will continue to be available to people aged 12 to 15 years. Permission to use a booster dose of the drug for immunocompromised persons will also continue to be valid.

“Our scientific and medical experts have done an incredibly thorough and thoughtful evaluation of this vaccine. We looked at scientific evidence and analyzed hundreds of thousands of pages of information to evaluate the safety and effectiveness of Comirnaty, ”said Peter Marks, director of the FDA’s Center for Biological Evaluation and Research. He stressed that the production lines producing the vaccine have also been thoroughly tested.

“The public and the medical community can rest assured that although we quickly approved this vaccine, it fully meets our high standards for vaccines in the United States,” concluded Peter Marks.

When deciding whether to approve the vaccine, the results of a study involving 40,000 people aged 16 and over were taken into account. Half of them received not the drug itself, but a placebo. The effectiveness of the vaccine is estimated at 91%. More than half of the participants in clinical trials were under medical supervision for four months or longer after taking the second dose.

The most common side effects reported by clinical trial participants were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. There was also an increased risk of myocarditis and pericarditis (inflammation in the heart muscle and the lining of the heart), especially within seven days after receiving the second dose of the drug. This risk is most at risk for men under 40, especially young men between the ages of 12 and 17. In some cases, patients with such inflammation required intensive care. There are no data on the long-term consequences of such violations.

The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalizations and death. In addition, the FDA has thoroughly evaluated post-marketing safety surveillance data for myocarditis and pericarditis following administration of Pfizer-BioNTech COVID-19 vaccine and determined that the data showed an increased risk, especially within seven days after the second dose. The observed risk is higher among men under the age of 40 compared to women and older men. The observed risk is highest in men between 12 and 17 years of age. Available short-term data suggest that symptoms have resolved in most people. However, some people required intensive care. No information is yet available on potential long-term health effects. The prescribing information for Comirnaty includes a warning about these risks.



Source link

novichoktimes

novichoktimes

Next Post

Police in Moscow came to hundreds of people, demanding to write a statement about a data breach from a database associated with Navalny's projects

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

In St. Petersburg, an artist was detained who created an art object in the form of feces on the Field of Mars

1 year ago

“I don’t know when my space journey will end or if it will end at all.” Navalny wrote about the anniversary of his return to Russia

1 year ago

Popular News

    Join Novichok (Moscow) Times

    Novichok (Moscow) Times

    Check out how you can help
    Novichok (Moscow) Times and its causes.

    Usefull Links

    • Home
    • CARTOONS
    • RUSSIA
    • COMING SOON
      • CZECHIA
      • RUSSIA
      • SWITZERLAND
      • USA
    • BELLINGCAT
    • THE INSIDER
    • NAVALNY

    Meta

    • Register
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About Us

    The Novichok (Moscow) Times is a global news source that promotes justice as well as the story. Founded by former personal training coach and fitness competitor Petr Pav, the Novichok Times delivers true news from all corners the world. It exists to honor all of those who do not enjoy the same level of journalistic freedom.

    • RUSSIA
    • CARTOONS
    • COMING SOON
    • News

    © 2021 Novichok (Moscow) Times

    No Result
    View All Result
    • Home
    • CARTOONS
    • RUSSIA
    • COMING SOON
      • CZECHIA
      • RUSSIA
      • SWITZERLAND
      • USA
    • BELLINGCAT
    • THE INSIDER
    • NAVALNY

    © 2021 Novichok (Moscow) Times

    Welcome Back!

    Login to your account below

    Forgotten Password? Sign Up

    Create New Account!

    Fill the forms bellow to register

    All fields are required. Log In

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    en English
    af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu